Dottikon, Switzerland
Dottikon, Switzerland

Time filter

Source Type

This report studies Laboratory Chemicals in Global Market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering  AMPAC Fine Chemicals  AppliChem GmbH  Argus Chemicals  Aurora Fine Chemicals  Avantor Performance Materials  BD Biosciences  Beckman Coulter Inc.  BioMerieux  Biosynth  CALTAG Laboratories  Chemada Fine Chemicals Company Ltd.  Chemical Centre  Dottikon Exclusive Synthesis AG  EMD Chemicals Inc.  European Fine Chemicals Group  GE Healthcare  Honeywell Riedel-de Haen  Life Technologies Corporation  Lonza Biologics Ltd.  Merck Chemicals  Meridian Life Science Inc.  Mitsubishi Rayon Co., Ltd.  Morphisto GmbH  P&R Labpak Limited  PerkinElmer Inc.  Promega Corporation  QIAGEN  R&D Systems  SAFC Biosciences Inc.  Samsung Fine Chemicals Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Laboratory Chemicals in these regions, from 2011 to 2021 (forecast), like  North America  Europe  China  Japan  Southeast Asia  India  Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into  Molecular Biology  Cytokine and Chemokine Testing  Carbohydrate Analysis  Immunochemistry  Cell/Tissue Culture  Environmental Testing  Biochemistry  Others  Split by application, this report focuses on consumption, market share and growth rate of Laboratory Chemicals in each application, can be divided into  Academic  Environmental  Healthcare  Research & Development for Life Sciences  Quality Control  Others Global Laboratory Chemicals Market Research Report 2016  1 Laboratory Chemicals Market Overview  1.1 Product Overview and Scope of Laboratory Chemicals  1.2 Laboratory Chemicals Segment by Type  1.2.1 Global Production Market Share of Laboratory Chemicals by Type in 2015  1.2.2 Molecular Biology  1.2.3 Cytokine and Chemokine Testing  1.2.4 Carbohydrate Analysis  1.2.5 Immunochemistry  1.2.6 Cell/Tissue Culture  1.2.7 Environmental Testing  1.2.8 Biochemistry  1.2.9 Others  1.3 Laboratory Chemicals Segment by Application  1.3.1 Laboratory Chemicals Consumption Market Share by Application in 2015  1.3.2 Academic  1.3.3 Environmental  1.3.4 Healthcare  1.3.5 Research & Development for Life Sciences  1.3.6 Quality Control  1.3.7 Others  1.4 Laboratory Chemicals Market by Region  1.4.1 North America Status and Prospect (2011-2021)  1.4.2 Europe Status and Prospect (2011-2021)  1.4.3 China Status and Prospect (2011-2021)  1.4.4 Japan Status and Prospect (2011-2021)  1.4.5 Southeast Asia Status and Prospect (2011-2021)  1.4.6 India Status and Prospect (2011-2021)  1.5 Global Market Size (Value) of Laboratory Chemicals (2011-2021) 2 Global Laboratory Chemicals Market Competition by Manufacturers  2.1 Global Laboratory Chemicals Capacity, Production and Share by Manufacturers (2015 and 2016)  2.2 Global Laboratory Chemicals Revenue and Share by Manufacturers (2015 and 2016)  2.3 Global Laboratory Chemicals Average Price by Manufacturers (2015 and 2016)  2.4 Manufacturers Laboratory Chemicals Manufacturing Base Distribution, Sales Area and Product Type  2.5 Laboratory Chemicals Market Competitive Situation and Trends  2.5.1 Laboratory Chemicals Market Concentration Rate  2.5.2 Laboratory Chemicals Market Share of Top 3 and Top 5 Manufacturers  2.5.3 Mergers & Acquisitions, Expansion 3 Global Laboratory Chemicals Capacity, Production, Revenue (Value) by Region (2011-2016)  3.1 Global Laboratory Chemicals Capacity and Market Share by Region (2011-2016)  3.2 Global Laboratory Chemicals Production and Market Share by Region (2011-2016)  3.3 Global Laboratory Chemicals Revenue (Value) and Market Share by Region (2011-2016)  3.4 Global Laboratory Chemicals Capacity, Production, Revenue, Price and Gross Margin (2011-2016)  3.5 North America Laboratory Chemicals Capacity, Production, Revenue, Price and Gross Margin (2011-2016)  3.6 Europe Laboratory Chemicals Capacity, Production, Revenue, Price and Gross Margin (2011-2016)  3.7 China Laboratory Chemicals Capacity, Production, Revenue, Price and Gross Margin (2011-2016)  3.8 Japan Laboratory Chemicals Capacity, Production, Revenue, Price and Gross Margin (2011-2016)  3.9 Southeast Asia Laboratory Chemicals Capacity, Production, Revenue, Price and Gross Margin (2011-2016)  3.10 India Laboratory Chemicals Capacity, Production, Revenue, Price and Gross Margin (2011-2016) For more information or any query mail at [email protected]


Bachle F.,University of Basel | Bachle F.,Dottikon Exclusive Synthesis AG | Fleischer I.,University of Basel | Fleischer I.,University of Regensburg | Pfaltz A.,University of Basel
Advanced Synthesis and Catalysis | Year: 2015

In extension of a concept of Lloyd-Jones, based on the combination of a racemic catalyst with a scalemic substrate, we have recently developed a method for determining the enantioselectivity of a chiral catalyst from its racemic form by mass spectrometric screening of a non-equal mixture of two mass-labeled quasi-enantiomeric substrates. After an initial proof of principle using palladium-catalyzed allylic substitution as test reaction, we report now the successful application of this approach to the screening of chiral amines as catalysts for the enantioselective Michael addition to α,β-unsaturated aldehydes. The results confirm that our method allows fast and reliable evaluation of chiral racemic catalysts. This opens up new possibilities for investigating catalyst structures that are not easily available in enantiomerically pure form. © 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.


Hu Q.,Saarland University | Jagusch C.,Dottikon Exclusive Synthesis AG | Hille U.E.,Saarland University | Haupenthal J.,Saarland University | Hartmann R.W.,Saarland University
Journal of Medicinal Chemistry | Year: 2010

Androgens are well-known to stimulate prostate cancer (PC) growth. Thus, blockade of androgen production in testes and adrenals by CYP17 inhibition is a promising strategy for the treatment of PC. Moreover, many PC patients suffer from glucocorticoid overproduction, and importantly mutated androgen receptors can be stimulated by glucocorticoids. In this study, the first dual inhibitor of CYP17 and CYP11B1 (the enzyme responsible for the last step in glucocorticoid biosynthesis) is described. A series of biphenylmethylene pyridines has been designed, synthesized, and tested as CYP17 and CYP11B1 inhibitors. The most active compounds were also tested for selectivity against CYP11B2 (aldosterone synthase), CYP19 (aromatase), and hepatic CYP3A4. In detail, compound 6 was identified as a dual inhibitor of CYP17/CYP11B1 (IC50 values of 226 and 287 nM) showing little inhibition of the other enzymes as well as compound 9 as a selective, highly potent CYP17 inhibitor (IC50 = 52 nM) exceeding abiraterone in terms of activity and selectivity. © 2010 American Chemical Society.


Hu Q.,Saarland University | Yin L.,Saarland University | Yin L.,ElexoPharm GmbH | Jagusch C.,Saarland University | And 3 more authors.
Journal of Medicinal Chemistry | Year: 2010

CYP17 inhibition is a promising therapy for prostate cancer (PC) because proliferation of 80% of PC depends on androgen stimulation. Introduction of isopropylidene substituents onto the linker of biphenylmethylene 4-pyridines resulted in several strong CYP17 inhibitors, which were more potent and selective, regarding CYP 11B1, 11B2, 19 and 3A4, than the drug candidate abiraterone. © 2010 American Chemical Society.


News Article | March 21, 2016
Site: cen.acs.org

The Drug, Chemical & Associated Technologies Association’s annual dinner, an event that’s been called the largest black-tie gathering in New York City, was held last week for the 90th time, at the Waldorf Astoria New York hotel . Suppliers of chemistry and other services to the pharmaceutical industry were there in force for meetings with customers and to announce investments in new capabilities and manufacturing capacity. The Swiss firm Dottikon Exclusive Synthesis said it would . . .


Hansen M.M.,Eli Lilly and Company | Jarmer D.J.,Eli Lilly and Company | Arslantas E.,Dottikon Exclusive Synthesis AG | DeBaillie A.C.,Eli Lilly and Company | And 19 more authors.
Organic Process Research and Development | Year: 2015

An efficient synthesis of LY2886721 (1) in five steps and 46% overall yield from the chiral nitrone cycloadduct 2 is presented. Minimizing formation of a des-fluoro impurity during hydrogenolysis to cleave the isoxazolidine ring and remove the benzyl chiral auxiliary was a key challenge. Installation of the aminothiazine moiety required careful stoichiometry control of the reagents BzNCS and CDI, including in situ conversion monitoring, to minimize byproduct formation. A remarkably regioselective peptide coupling afforded 1 without competing acylation at the aminothiazine nitrogen or bis-acylation. Consideration of the combined chemistry and crystallization process identified an optimal solvent system for the peptide coupling and a reactive crystallization that afforded 1 in high purity and with physical property control. A slurry milling operation near the end of the crystallization, followed by "pH cycles" to digest fines formed during milling, significantly reduced the crystal aspect ratio and provided desirable API bulk density and powder flow properties. © 2015 American Chemical Society.


Shi X.,Biogen Idec | Chang H.,Biogen Idec | Grohmann M.,Dottikon Exclusive Synthesis AG | Kiesman W.F.,Biogen Idec | Kwok D.-I.A.,Biogen Idec
Organic Process Research and Development | Year: 2015

A two-step pharmaceutical manufacturing process was developed for the large-scale preparation of 6-chloro-9-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-9H-purin-2-amine methanesulfonic acid salt (4) from commercially available starting materials. In the first step, the benzylpurine free base (3) was prepared by benzylation of 6-chloro-9H-purin-2-amine (1) with 2-(chloromethyl)-4-methoxy-3,5-dimethylpyridine hydrochloride (2). The benzylpurine free base was then directly converted into the methanesulfonic acid salt. It was necessary to charge the pyridine hydrochloride 2 in portions into the mixture of K2CO3 (-325 mesh) and the chloropurine compound 1 in dimethylacetamide (DMA). The major regioisomeric impurity (6), formed by N7 benzylation, and inorganic salts were removed by filtration. Treatment of the DMA filtrate with MsOH afforded the target salt with negligible degradation. In the second step, recrystallization of the crude salt from DMSO-EtOAc with seeding gave crystalline API in high yield and purity despite the hydrolytic instability of the product in solution. © 2015 American Chemical Society.


Kolis S.P.,Eli Lilly and Company | Hansen M.M.,Eli Lilly and Company | Arslantas E.,Dottikon Exclusive Synthesis AG | Brandli L.,Dottikon Exclusive Synthesis AG | And 14 more authors.
Organic Process Research and Development | Year: 2015

A scalable, asymmetric synthesis of (3aS,6aS)-6a-(5-bromo-2-fluorophenyl)-1-((R)-1-phenylpropyl)tetrahydro-1H,3H-furo[3,4-c]isoxazole, a key intermediate in the synthesis of LY2886721, is reported. Highlights of the synthesis include the development of an asymmetric [3 + 2] intramolecular cycloaddition facilitated by trifluoroethanol, and the development of a new synthesis of (R)-N-(1-phenylpropyl)hydroxylamine tosylate which proceeds through a p-anisaldehyde imine and avoids the formation of toxic hydrogen cyanide gas as a byproduct. The synthesis proceeds over four steps and provides the product in 36% overall yield. © 2015 American Chemical Society.

Loading Dottikon Exclusive Synthesis AG collaborators
Loading Dottikon Exclusive Synthesis AG collaborators